Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer ziprasidone

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Oral form of the antipsychotic agent, formerly known as Zeldox, is approved Feb. 5. A March launch is planned. Although the drug is not restricted to second-line use, labeling recommends physicians first consider prescribing other agents that have lower rates of QT prolongation. "Whether ziprasidone will cause torsades de pointes or increase the rate of sudden death is not yet known," labeling states. A boxed warning, recommended by FDA's Psychopharmacologic Drugs Advisory Committee, is not in labeling. Among the potential tradenames under discussion is Geodon. An intramuscular formulation of ziprasidone is scheduled for review by the psychopharm committee Feb. 1

You may also be interested in...



UK IVDs Firms Working Flat Out On COVID-19 Tests, As Govt Promises Test Capacity Increase

Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

Topics

UsernamePublicRestriction

Register

PS001368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel